左西孟旦联合重组人脑利钠肽治疗老年难治性心力衰竭临床分析

Clinical study of levosimendan combined with recombinant human brain natriuretic peptide on elderly patients with refractory heart failure

目的观察左西孟旦联合重组人脑利钠肽对老年难治性心力衰竭患者的疗效。方法选取2021年9月~2022年8月于我院住院的老年(年龄>65岁)难治性心力衰竭患者70例,随机分为对照组和观察组,每组35例,两组均给予常规抗心衰基础治疗,对照组给予左西孟旦治疗,观察组给予左西孟旦及重组人脑利钠肽治疗。观察比较两组患者临床症状改善情况及患者血浆氨基末端脑钠肽前体(NT-proBNP)、左室射血分数(LVEF)水平变化。结果治疗48h后,两组临床症状均明显改善,观察组有效率高于对照组,两组比较,差异有统计学意义(P<0.05)。观察组血浆NT-proBNP低于对照组,LVEF高于对照组,两组比较,差异有统计学意义(P<0.05)。结论左西孟旦联合重组人脑利钠肽能显著改善老年难治性心力衰竭患者的临床症状,降低血浆NT-proBNP水平、提高LVEF,且安全性高。

Objective To investigate the effect of levosimendan combined with recombinant human brain natriuretic peptide(rhBNP)on elderly patients with refractory heart failure.Methods Seventy elderly patients with refractory heart failure admitted to our hospital from September 2021 to August 2022 were randomly divided into an observation group and a control group,with 35 cases in each group.Both of the two groups were given basis of conventional treatment,while the control group was treated with levosimendan and the observation group was treated with levosimendan and rhBNP.The clinical efficacy,NT-proBNP and LVEF were compared between the two groups.Results Forty-eight hours after treatment,the clinical symptoms of both groups were all improved,and the effective rate in the observation group was higher than that in the control group,the difference was statistically significant(P<0.05).After treatment,NT-proBNP in the observation group was lower than that in the control group,while LVEF in the observation group was higher than that in the control group(P<0.05).Conclusion Levosimendan combined with recombinant human brain natriuretic peptide can significantly improve the clinical symptoms,reduce the concentration of NT-proBNP and increase the level of LVEF on elderly patients with refractory heart failure,with high safety.